Asset
DENATONIUM ACETATE MONOHYDRATE
Aardvark Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05153434 | phase2 | completed | 2022-05-27 | 2024-09-24 | Aardvark Therapeutics, Inc. | A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome |
| NCT06828861 | phase3 | terminated | 2024-12-20 | 2026-05-07 | Aardvark Therapeutics, Inc. | ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial |
| NCT05215847 | phase2 | completed | 2022-03-01 | 2023-02-03 | Aardvark Therapeutics, Inc. | Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery |
| NCT05121441 | phase2 | completed | 2021-11-15 | 2022-11-09 | Aardvark Therapeutics, Inc. | Study to Evaluate ARD-101 in Adults With Obesity |
| NCT07197034 | phase3 | terminated | 2024-07-23 | 2026-04-15 | Aardvark Therapeutics, Inc. | The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial |
FDA applications (0)
This company has no applications containing this asset.